TY - JOUR 
A1 - Pérez-Valero, Ignacio
AU - González-Baeza, Alicia
AU - Estébanez, Miriam
AU - Monge, Susana
AU - Montes-Ramírez, M. L.
AU - Bayón, Carmen
AU - Pulido, Federico
AU - Bernardino, José Ignacio
AU - Zamora, F. X.
AU - González García, J. J.
AU - Lagarde, María
AU - Hernando Jeréz, María Asunción
AU - Arnalich, Francisco
AU - Arribas, José R.
T1 - A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals
Y1 - 2014
SN - 10584838
UR - http://hdl.handle.net/11268/3820
AB - The evolution of neurocognitive performance in aviremic human immunodeficiency virus (HIV)–
 positive patients treated with <3 antiretrovirals is unknown.
 Methods. We prospectively included aviremic (≥1 year) HIV-positive patients, without concomitant major neurocognitive
 confounders, currently receiving boosted lopinavir or darunavir as monotherapy (n = 67) or triple antiretroviral
 therapy (ART) (n = 67) for ≥1 year. We evaluated neurocognitive function (7 domains) at baseline and
 after 1 year.We performed analysis of covariance to evaluate if 1 additional year of exposure tomonotherapy compared
 with triple ART had an effect on Global Deficit Score (GDS) changes after adjustment for potential confounders. We
 also compared the evolution of neurocognitive performance and impairment rates.
 Results. Intention-to-treat analysis showed that monotherapy did not influence 1-year GDS change after adjustment
 for significant confounders (age, ethnicity, duration of therapy, hepatitis C virus status, and HOMA-IR index); the
 adjusted effect was −0.04 (95% confidence interval, −.14 to .05; P = .38). Neurocognitive stability was observed with
 monotherapy and triple therapy (GDS crude mean change, −0.09 [95% confidence interval, −.16 to −.01] vs −0.08
 [−.14 to −.02]), after 1 year of follow-up, similar proportions of patients changed neurocognitive status from impaired
 to unimpaired (monotherapy, 4 of 18 [22.2%]; triple therapy, 4 of 19 [21.1%]; P = .91) and vice versa (monotherapy,
 5 of 44 [10.2%] and triple therapy, 3 of 45 [6.3%]; P = .48). Similar results were observed in an on-treatment analysis
 and with use of clinical ratings instead of GDS changes.
 Conclusions. The number of antiretrovirals included in the ART regimen does not seem to influence the evolution
 of neurocognitive function in HIV-infected patients with suppressed plasma viremia.
KW - SIDA
KW - Sida
LA - eng
ER -